Skip to main content
Skip to main content
GRDN logo

Guardian Pharmacy Services, Inc. (GRDN)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Guardian Pharmacy Services, Inc. (GRDN) trades at $35.40 with AI Score 51/100 (Hold). Guardian Pharmacy Services provides technology-enabled pharmacy solutions to long-term care facilities in the United States, focusing on lower acuity settings. Market cap: 3B, Sector: Healthcare.

Last analyzed: Feb 5, 2026
Guardian Pharmacy Services provides technology-enabled pharmacy solutions to long-term care facilities in the United States, focusing on lower acuity settings. Their services include clinical support, drug dispensing, and administration, all enhanced by data-driven insights.
51/100 AI Score Target $38.00 (+7.3%) MCap 3B Vol 350K

Guardian Pharmacy Services, Inc. (GRDN) Healthcare & Pipeline Overview

CEOFred Burke
Employees3400
HeadquartersAtlanta, US
IPO Year2016

Guardian Pharmacy Services delivers tailored pharmacy solutions to long-term care facilities, leveraging technology and data analytics to optimize medication management and clinical outcomes, positioning them as a key player in the evolving healthcare landscape with a P/E ratio of 50.75.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Feb 5, 2026

Investment Thesis

Guardian Pharmacy Services presents a notable research candidate due to its strategic focus on the underserved market of lower acuity long-term care facilities. The company's technology-enabled solutions, including Guardian Compass and GuardianShield Programs, drive efficiency and improve clinical outcomes, enhancing its value proposition to LTCFs. With a market capitalization of $2.08 billion and a profit margin of 2.9%, Guardian Pharmacy Services demonstrates financial stability and growth potential. Key value drivers include the increasing demand for specialized pharmacy services in LTCFs, the company's ability to leverage data analytics to optimize operations, and its established presence in a fragmented market. Upcoming catalysts include potential expansion into new geographic markets and the development of innovative service offerings. The company's beta of 0.96 suggests lower volatility compared to the broader market, making it a noteworthy option for risk-averse investors.

Based on FMP financials and quantitative analysis

Key Highlights

  • Market capitalization of $2.08 billion reflects substantial investor confidence in Guardian Pharmacy Services' market position and growth prospects.
  • P/E ratio of 50.75 indicates investor expectations for future earnings growth, driven by increasing demand for specialized pharmacy services.
  • Gross margin of 19.7% demonstrates the company's ability to maintain profitability while delivering value-added services to long-term care facilities.
  • A beta of 0.96 suggests the stock is slightly less volatile than the market, offering a degree of stability in investment portfolios.
  • The company's focus on technology-enabled solutions, such as Guardian Compass, differentiates it from competitors and enhances its operational efficiency.

Competitors & Peers

Strengths

  • Technology-enabled solutions enhance efficiency and improve clinical outcomes.
  • Focus on lower acuity LTCFs allows for specialized service offerings.
  • Established relationships with LTCF operators provide a stable customer base.
  • Data-driven insights enable continuous improvement and optimization.

Weaknesses

  • Reliance on LTCF reimbursement models exposes the company to regulatory risks.
  • Limited geographic diversification may constrain growth potential.
  • Profit margin of 2.9% is relatively low compared to industry peers.
  • High P/E ratio of 50.75 suggests the stock may be overvalued.

Catalysts

  • Potential acquisitions of smaller pharmacy providers to expand market share.
  • Increasing demand for specialized pharmacy services in LTCFs due to the aging population.
  • Continued adoption of technology-enabled solutions by LTCFs to improve efficiency and reduce costs.
  • Development and launch of new service offerings, such as specialized medication management programs.

Risks

  • Changes in government regulations and reimbursement policies could negatively impact revenue.
  • Economic downturns may reduce occupancy rates in LTCFs, leading to lower demand for pharmacy services.
  • Increasing competition from larger pharmacy chains and specialized providers.
  • Cybersecurity threats and data breaches could compromise patient information and damage the company's reputation.

Growth Opportunities

  • Expansion into new geographic markets represents a significant growth opportunity for Guardian Pharmacy Services. By extending its reach beyond its current footprint, the company can tap into underserved markets and increase its customer base. The market size for LTC pharmacy services is estimated at over $20 billion annually, providing ample room for growth. This expansion can be achieved through strategic acquisitions or organic growth, with a timeline of 3-5 years for significant market penetration. The company's established infrastructure and expertise in serving LTCFs provide a competitive advantage in entering new regions.
  • Development of innovative service offerings, such as specialized medication management programs for specific conditions (e.g., dementia, diabetes), can drive revenue growth and enhance customer loyalty. The market for specialized pharmacy services is growing rapidly, with a projected annual growth rate of 8-10%. Guardian Pharmacy Services can leverage its data analytics capabilities to identify unmet needs and develop tailored solutions. This initiative can be implemented within 1-2 years, with ongoing refinement and expansion based on market feedback. The company's clinical expertise and technology platform provide a strong foundation for innovation.
  • Strategic partnerships with LTCF operators can create synergistic opportunities and drive customer acquisition. By collaborating with leading LTCF chains, Guardian Pharmacy Services can gain access to a large pool of potential customers and streamline its sales and marketing efforts. The market for LTCF services is highly fragmented, with numerous regional and national operators. These partnerships can be established within 6-12 months, with ongoing collaboration to optimize service delivery and enhance customer satisfaction. The company's reputation for quality and reliability makes it an attractive partner for LTCF operators.
  • Leveraging data analytics to improve medication adherence and reduce healthcare costs can create value for both LTCFs and payers. By identifying patients at risk of non-adherence and implementing targeted interventions, Guardian Pharmacy Services can improve clinical outcomes and reduce hospital readmissions. The market for medication adherence solutions is growing rapidly, driven by the increasing focus on value-based care. This initiative can be implemented within 1-2 years, with ongoing monitoring and refinement based on patient outcomes. The company's data analytics platform and clinical expertise provide a competitive advantage in this area.
  • Expanding into the specialty pharmacy market for LTCFs represents a high-growth opportunity. Specialty medications, such as biologics and infused therapies, are increasingly used in LTCFs to treat complex conditions. The market for specialty pharmacy services is growing at a double-digit rate, driven by the increasing prevalence of chronic diseases and the availability of new therapies. Guardian Pharmacy Services can leverage its existing infrastructure and expertise to enter this market, with a timeline of 2-3 years for significant market penetration. The company's focus on technology and data analytics will be critical for managing the complexities of specialty pharmacy.

Opportunities

  • Expansion into new geographic markets can drive revenue growth.
  • Development of innovative service offerings can enhance customer loyalty.
  • Strategic partnerships with LTCF operators can create synergistic opportunities.
  • Leveraging data analytics to improve medication adherence can reduce healthcare costs.

Threats

  • Increasing competition from larger pharmacy chains and specialized providers.
  • Changes in government regulations and reimbursement policies.
  • Economic downturns may reduce occupancy rates in LTCFs.
  • Cybersecurity threats and data breaches could compromise patient information.

Competitive Advantages

  • Specialized Focus: Concentrating on lower acuity LTCFs allows for tailored service offerings and deeper market penetration.
  • Technology-Enabled Solutions: Guardian Compass and GuardianShield Programs provide a competitive edge through data-driven insights and enhanced safety protocols.
  • Established Relationships: Long-standing partnerships with LTCFs create a stable revenue stream and barriers to entry for new competitors.
  • Scalable Infrastructure: The company's infrastructure is designed to efficiently serve a growing number of LTCFs across multiple geographic locations.

About GRDN

Founded in 2003 and headquartered in Atlanta, Georgia, Guardian Pharmacy Services, Inc. emerged to address the unique pharmaceutical needs of residents in long-term health care facilities (LTCFs). Recognizing the increasing demand for specialized pharmacy services within this sector, the company developed a comprehensive suite of technology-enabled solutions designed to improve medication management and clinical outcomes. Guardian Pharmacy Services primarily caters to lower acuity LTCFs, including assisted living facilities, behavioral health facilities, and group homes. Their core offerings encompass individualized clinical support, precise drug dispensing, and efficient administration capabilities, all tailored to the specific requirements of each facility and its residents. A key differentiator is Guardian Compass, a proprietary platform that utilizes data from the company's data warehouse to provide local pharmacies with actionable insights for business planning, tracking, and optimization. Complementing this is the GuardianShield Programs, designed to enhance safety and compliance within LTCFs. With 3,400 employees, Guardian Pharmacy Services has established a significant presence in the US market, providing a vital link between pharmaceutical care and the well-being of vulnerable populations within long-term care settings. The company's commitment to innovation and data-driven solutions positions it as a leader in the evolving landscape of specialized pharmacy services.

What They Do

  • Provide technology-enabled pharmacy services to long-term care facilities (LTCFs).
  • Offer individualized clinical support to residents in LTCFs.
  • Dispense medications accurately and efficiently.
  • Administer medications according to prescribed regimens.
  • Serve residents in lower acuity LTCFs, such as assisted living facilities.
  • Utilize Guardian Compass for data-driven business planning and optimization.
  • Implement GuardianShield Programs to enhance safety and compliance in LTCFs.

Business Model

  • Generate revenue through the dispensing of prescription medications to residents in LTCFs.
  • Provide clinical consulting services to LTCFs, optimizing medication management and patient care.
  • Offer technology solutions, such as Guardian Compass, to enhance operational efficiency for LTCFs.
  • Establish contracts with LTCFs to provide comprehensive pharmacy services.

Industry Context

Guardian Pharmacy Services operates within the medical distribution industry, a segment of the healthcare sector experiencing steady growth due to the aging population and increasing demand for long-term care services. The market is characterized by a mix of large national players and smaller regional providers. Guardian Pharmacy Services distinguishes itself through its focus on lower acuity LTCFs and its technology-driven approach. The industry is subject to regulatory scrutiny and evolving reimbursement models, requiring companies to adapt and innovate to maintain profitability. The company's commitment to data analytics and customized solutions positions it favorably within this competitive landscape, allowing it to capture market share and drive growth.

Key Customers

  • Assisted living facilities (ALFs)
  • Behavioral health facilities
  • Group homes
  • Other lower acuity long-term care facilities
AI Confidence: 73% Updated: Feb 5, 2026

GRDN Financials

GRDN Price Today & Live Chart

Guardian Pharmacy Services, Inc. (GRDN) stock price: $35.40 (-1.10, -3.01%)

GRDN Latest News

GRDN Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GRDN.

Price Targets

Consensus target: $38.00

GRDN MoonshotScore

51/100

What does this score mean?

The MoonshotScore rates GRDN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Latest Guardian Pharmacy Services, Inc. Analysis

What Investors Ask About Guardian Pharmacy Services, Inc. (GRDN) — Healthcare

What does Guardian Pharmacy Services, Inc. do?

Guardian Pharmacy Services, Inc. provides comprehensive pharmacy solutions tailored for residents in long-term care facilities (LTCFs) across the United States. They specialize in serving lower acuity LTCFs, such as assisted living and behavioral health facilities, offering individualized clinical support, precise drug dispensing, and efficient medication administration. Their proprietary technology, including Guardian Compass, leverages data analytics to optimize pharmacy operations and enhance patient care. By focusing on this niche market and providing technology-driven solutions, Guardian Pharmacy Services aims to improve medication management and clinical outcomes for vulnerable populations in long-term care settings.

Is GRDN stock worth researching?

GRDN stock presents a mixed investment profile. The company's focus on the growing LTCF market and its technology-enabled solutions offer significant growth potential. However, the high P/E ratio of 50.75 suggests that the stock may be overvalued, and the relatively low profit margin of 2.9% warrants careful consideration. Investors should weigh the company's growth prospects against its valuation and potential risks, such as regulatory changes and increasing competition. A thorough analysis of the company's financial performance and market position is essential before making an investment decision. The absence of a dividend yield may deter some investors.

What are the main risks for GRDN?

Guardian Pharmacy Services faces several key risks. Changes in government regulations and reimbursement policies for LTCFs could significantly impact revenue. Increasing competition from larger pharmacy chains and specialized providers may erode market share. Economic downturns could reduce occupancy rates in LTCFs, leading to lower demand for pharmacy services. Additionally, cybersecurity threats and data breaches pose a significant risk to patient information and the company's reputation. Investors should carefully consider these potential risks before investing in GRDN stock.

What are the key factors to evaluate for GRDN?

Guardian Pharmacy Services, Inc. (GRDN) currently holds an AI score of 51/100, indicating moderate score. The stock trades at a P/E of 45.5x, above the S&P 500 average (~20-25x), suggesting high growth expectations. Analysts target $38.00 (+7% from $35.40). Key strength: Technology-enabled solutions enhance efficiency and improve clinical outcomes. Primary risk to monitor: Changes in government regulations and reimbursement policies could negatively impact revenue. This is not financial advice.

How frequently does GRDN data refresh on this page?

GRDN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven GRDN's recent stock price performance?

Recent price movement in Guardian Pharmacy Services, Inc. (GRDN) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $38.00 implies 7% upside from here. Notable catalyst: Technology-enabled solutions enhance efficiency and improve clinical outcomes. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider GRDN overvalued or undervalued right now?

Determining whether Guardian Pharmacy Services, Inc. (GRDN) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 45.5. Analysts target $38.00 (+7% from current price), suggesting analysts see the stock near fair value. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying GRDN?

Before investing in Guardian Pharmacy Services, Inc. (GRDN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Financial data is based on available information and may be subject to change.
  • Market analysis is based on current industry trends and may not accurately predict future outcomes.
  • This dossier is for informational purposes only and does not constitute investment advice.
Data Sources

Popular Stocks